Analyst consensus rating
AbbVie Analyst Rating: Buy
Direct answer
AbbVie's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $306.42.
Forecast evidence checked November 4, 2026.
Get free AbbVie email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $286.00
- Average price target
- $306.42
- High price target
- $350.00
- Low price target
- $237.00
- Low target gap
- -17.1%
- Target upside
- +7.1%
- High target gap
- +22.4%
- Target range width
- 39.5%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AbbVie?
AbbVie has a verified Buy consensus. The same dataset has an average price target of $306.42.
How far are AbbVie's low and high targets from the recorded price?
The low target implies -17.1%, while the high target implies +22.4%.
How many analysts are included in AbbVie's consensus?
The verified consensus includes 26 analysts.
How is AbbVie's target upside or downside calculated?
The average target of $306.42 is divided by the recorded price of $286.00, then one is subtracted to produce +7.1%. This does not guarantee a future return.
When was AbbVie's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.